# Depo-Provera & meningioma litigation

> Educational mass tort overview from DrugsMonitor.com. Not legal or medical advice.

**Canonical URL:** https://drugsmonitor.com/case/depo-provera-meningioma-lawsuit
**Last updated:** 2026-06-11

## Key facts

- **Matter:** Depo-Provera / Meningioma
- **Status:** Emerging
- **Scope:** United States — national overview
- **Drug safety page:** https://drugsmonitor.com/drug-info/depo-provera-meningioma-lawsuit

## Overview

Emerging litigation examines whether long-acting injectable contraception (Depo-Provera and equivalents containing medroxyprogesterone acetate) is associated with an increased risk of meningiomas—often benign brain tumors that can still require surgery or cause serious symptoms.

### Scientific and regulatory backdrop

European pharmacovigilance reviews and studies cited in litigation prompted updated labeling abroad and heightened patient questions in the United States. Plaintiffs argue earlier warnings should have reflected suspected risk with prolonged exposure.

Defendants will likely dispute general causation, dosing history, tumor biology, and confounding hormones or genetics.

### Procedural landscape

Unlike older MDLs, Depo-meningioma claims may still be filed in various state and federal courts pending any future consolidation. That flexibility can complicate coordination but also affects choice of counsel and applicable law.

Early cases may influence whether an MDL forms and where.

---

*DrugsMonitor.com is not a law firm. For medical decisions consult a licensed clinician; for legal decisions consult a qualified attorney.*